EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieStudienprotokollOpen Access · CC BY 4.0

Unresectable Intermediate-Size (3–5 cm) Colorectal Liver Metastases: Stereotactic Ablative Body Radiotherapy Versus Microwave Ablation (COLLISION-XL): Protocol of a Phase II/III Multicentre Randomized Controlled Trial

Susan van der Lei, Madelon Dijkstra, Sanne Nieuwenhuizen, Hannah H Schulz, Danielle J W Vos, Kathelijn S Versteeg, Tineke E Buffart, Rutger-Jan Swijnenburg, Jan J J de Vries, Anna M E Bruynzeel, M Petrousjka van den Tol, Hester J Scheffer und 4 weitere

CardioVascular and Interventional Radiology · 2023

DOI: 10.1007/s00270-023-03498-8 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift CardioVascular and Interventional Radiology, 2023. Verfasst von Susan van der Lei und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Nuclear Medicine, Amsterdam UMC, Location VUmc, De Boelelaan 1117, 1081, HV, Amsterdam, The Netherlands. s.vanderlei@amst…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Liver Neoplasms, Radiosurgery. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Johnson and Johnson.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although microwave ablation (MWA) has a low complication rate and good efficacy for small-size (≤ 3 cm) colorectal liver metastases (CRLM), local control decreases with increasing size. Stereotactic body radiotherapy (SBRT) is gaining interest as a potential means to treat intermediate-size CRLM and might be less susceptible to increasing volume. The objective of this study is to compare the efficacy of MWA to SBRT in patients with unresectable, intermediate-size (3–5 cm) CRLM.

Methods

In this two-arm, multicentre phase II/ III randomized controlled trial, 68 patients with 1–3 unresectable, intermediate-size CRLM suitable for both MWA and SBRT, will be included. Patients will be treated with MWA or SBRT as randomised. The Primary endpoint is local tumour progression-free survival (LTPFS) at 1 year (intention-to-treat analysis). Main secondary endpoints are overall survival, overall and distant progression-free survival (DPFS), local control (LC) and procedural morbidity and mortality and assessment of pain and quality of life.

Discussion

Current guidelines lack clear recommendations for the local treatment of liver only intermediate-size, unresectable CRLM and studies comparing curative intent SBRT and thermal ablation are scarce. Although safety and feasibility to eradicate tumours ≤ 5 cm have been established, both techniques suffer from lower LTPFS and LC rates for larger-size tumours. For the treatment of unresectable intermediate-size CRLM clinical equipoise has been reached. We have designed a two-armed phase II/ III randomized controlled trial directly comparing SBRT to MWA for unresectable CRLM 3–5 cm. Level of Evidence Level 1, phase II/ III Randomized controlled trial. Trial Registration : NCT04081168, September 9th 2019. Graphical Abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsLiver NeoplasmsRadiosurgeryHumansClinical Trials, Phase II as TopicMicrowavesMulticenter Studies as TopicQuality of LifeRandomized Controlled Trials as TopicTreatment OutcomeClinical Trials, Phase III as Topic

Stichwörter der Autor:innen

Colorectal cancerColorectal liver metastases (CRLM)Liver metastasesMicrowave ablation (MWA)RadiotherapyRandomized controlled trial (RCT)Stereotactic body radiotherapy (SBRT)Thermal ablation

Autor:innen und Institutionen

  • Department of Radiology and Nuclear Medicine, Amsterdam UMC, Location VUmc, De Boelelaan 1117, 1081, HV, Amsterdam, The Netherlands. s.vanderlei@amsterdamumc.nl.
  • Department of Radiology and Nuclear Medicine, Amsterdam UMC, Location VUmc, De Boelelaan 1117, 1081, HV, Amsterdam, The Netherlands.
  • Department of Medical Oncology, Amsterdam UMC, Location VUmc, Amsterdam, The Netherlands.
  • Department of Surgery, Amsterdam UMC, Location VUmc, Amsterdam, The Netherlands.
  • Department of Radiology and Nuclear Medicine, OLVG Hospital, Amsterdam, The Netherlands.
  • Department of Radiation Oncology, Amsterdam UMC, Location VUmc, Amsterdam, The Netherlands.

Förderung

  • Johnson and Johnson

Zitieren

APA

van der Lei, S., Dijkstra, M., Nieuwenhuizen, S., Schulz, H. H., Vos, D. J. W., Versteeg, K. S., Buffart, T. E., Swijnenburg, R. J., de Vries, J. J. J., Bruynzeel, A. M. E., van den Tol, M. P., Scheffer, H. J., Puijk, R. S., Haasbeek, C. J. A., Meijerink, M. R., & and COLLISION Trial Group (2023). Unresectable Intermediate-Size (3–5 cm) Colorectal Liver Metastases: Stereotactic Ablative Body Radiotherapy Versus Microwave Ablation (COLLISION-XL): Protocol of a Phase II/III Multicentre Randomized Controlled Trial. CardioVascular and Interventional Radiology. https://doi.org/10.1007/s00270-023-03498-8

Vancouver

van der Lei S, Dijkstra M, Nieuwenhuizen S, Schulz HH, Vos DJW, Versteeg KS, et al. Unresectable Intermediate-Size (3–5 cm) Colorectal Liver Metastases: Stereotactic Ablative Body Radiotherapy Versus Microwave Ablation (COLLISION-XL): Protocol of a Phase II/III Multicentre Randomized Controlled Trial. CardioVascular and Interventional Radiology. 2023. doi:10.1007/s00270-023-03498-8

BibTeX
@article{vanderLei2023,
  author = {van der Lei, Susan and Dijkstra, Madelon and Nieuwenhuizen, Sanne and Schulz, Hannah H and Vos, Danielle J W and Versteeg, Kathelijn S and Buffart, Tineke E and Swijnenburg, Rutger-Jan and de Vries, Jan J J and Bruynzeel, Anna M E and van den Tol, M Petrousjka and Scheffer, Hester J and Puijk, Robbert S and Haasbeek, Cornelis J A and Meijerink, Martijn R and and COLLISION Trial Group, and COLLISION Trial Group},
  title = {Unresectable Intermediate-Size (3–5 cm) Colorectal Liver Metastases: Stereotactic Ablative Body Radiotherapy Versus Microwave Ablation (COLLISION-XL): Protocol of a Phase II/III Multicentre Randomized Controlled Trial},
  journal = {CardioVascular and Interventional Radiology},
  year = {2023},
  doi = {10.1007/s00270-023-03498-8}
}
Kostenlos starten →